NCT04250155 2026-02-24An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsGenentech, Inc.Phase 1 Active not recruiting195 enrolled